Strategies and Concerns in the Sourcing of FDA-Regulated Products, Components & Services Michael A. Swit, Esq. Law Offices of Michael A. Swit 539 Samuel.

Slides:



Advertisements
Similar presentations
Basic Principles of GMP
Advertisements

What FDA Looks for When Inspecting IRBs and Sponsors Marian J. Serge Nurse Consultant Division of Bioresearch Monitoring Office of Compliance Center for.
Good Manufacturing Practice Regulations
Tips to a Successful Monitoring Visit
Medsafe – GMP update / release for supply / communicating quality issues Derek Fitzgerald Manager, Compliance Management 11 July 2013 RACI Pharmaceutical.
Annual Product Review (APR) Product Quality Review (PQR)
Common Mistakes & Audits 05/21/2014. Summary of audit findings by category.
Enforcement, Litigation and Compliance Conference December 8, 2014.
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
FDA Counsel.com Legal Strategies and Concerns in the Sourcing of FDA-Regulated Products, Components & Services Keys to a Win-Win Relationship with Your.
Regulatory Challenges in the Cell Preparation Facility Adrian Gee Center for Cell & Gene Therapy Regulatory Challenges in the Cell Preparation Facility.
GMP Document and Record Retention
Batch Reworking and Reprocessing
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
Quality control of raw materials In-process control
World Health Organization
FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO.
Legal and Regulatory Concerns in the Sourcing of FDA-Regulated Products, Components & Services Part 1 – The Impact of FDA Legal & Regulatory Requirements.
Field Investigators: ADE Detectives. Section One Introduction to the Team and Their Roles.
TELLEFSEN AND COMPANY, L.L.C. SEC Regulation SCI and Automation Review Policy Compliance March 2013 Proprietary and Confidential.
Session 6: Data Integrity and Inspection of e-Clinical Computerized Systems May 15, 2011 | Beijing, China Kim Nitahara Principal Consultant and CEO META.
Personnel Basic Principles of GMP Workshop on
Top Tactics for Maximizing GMP Compliance in Blue Mountain RAM Jake Jacanin, Regional Sales Manager September 18, 2013.
Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved. McGraw-Hill/Irwin 17-1 Chapter Seventeen Completing the Engagement Chapter Seventeen.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
World Health Organization
Quality Control Testing in Procurement Helene Möller, M.Pharm, PhD Interregional Seminar for Quality Control Laboratories involved in WHO Prequalification.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
FDA Regulatory Considerations in Launching Products Michael A. Swit, Esq. Vice President, Life Sciences WITI (Women In Technology International) San Diego.
November 2003 Slide 1 PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS AND BEST PRACTICES FORUM MANUFACTURING AND GMP ISSUES: PREPARING FOR AN FDA INSPECTION.
ASEAN GMP TRAINING MODULE PERSONNEL
Good Manufacturing Practices
Food & Drug Law Institute Conference on Products Liability For FDA Regulated Products January 26, 2005 Recalls: The First Smoke of A Mass Tort Overview.
FDA Regulatory review in Minutes: What Product Development Executives Need-to-Know. Specifically, frequent causes of recalls and related areas that investigators.
Carolyn Hommel Good Clinical Practice Program FDA February 25, 2004
Inspection Issues in the Analytical Laboratory: An FDA Perspective Yvonne McKnight Chemist US Food and Drug AdministrationPhone: x
Planning an Audit The Audit Process consists of the following phases:
5.01 Students will be able to understand the rights and responsibilities of consumers.
Top 10 Medical Device Citations
Good Manufacturing Practice. Good Manufacturing Practice Regulations Establishes minimum GMP for methods to be used, and the facilities or controls to.
Legal and Regulatory Concerns in the Sourcing of FDA-Regulated Products, Components & Services Part 1 – The Impact of FDA Legal & Regulatory Requirements.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
Important informations
1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.
Brette Kaplan, Esq. Erin Auerbach, Esq. Brustein & Manasevit, PLLC Spring Forum 2013
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
Legal and Regulatory Concerns in the Sourcing of FDA-Regulated Products, Components & Services Part 2 – The Contract and Related Legal Strategies Michael.
© 2011 Michigan State University and United Nations Industrial Development Organization, original at CC-BY-SA HACCP Principle.
Managing Sponsor/Investigator Relationships 5 th National Conference on Managing Legal Risks in Structuring and Conducting Clinical Trials American Conference.
Is Your Background Check Process Compliant?. 2 © Copyright 2015 ADP, LLC. Proprietary and Confidential Information. Agenda Privileged & Confidential.
FDA job description  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs,
0 Due Diligence Monitoring and Auditing of Third Party Vendors October 28, 2008 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Good Manufacturing Practice (GMP) Compliance: GMPs EXPLAINED.
WORKSHOP ON ACCREDITATION OF BODIES CERTIFYING MEDICAL DEVICES INT MARKET TOPIC 9 CH 8 ISO MEASUREMENT, ANALYSIS AND IMPROVEMENT INTERNAL AUDITS.
Quality Control significance in pharmaceutical industry
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
Slide 1 Standard Operating Procedures. Slide 2 Goal To review the standard operating procedures Creating the informed consent document Obtaining informed.
Responsibilities of Sponsor, Investigator and Monitor
Brought to you by: GMP Inspection Lessons Early results from the first few years of inspections have highlighted some common violations of the GMP regulation.

Responsibilities of Sponsor, Investigator and Monitor
IRB reporting updates.
Lesson 7: BRITE Seminar: GMP II
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
Upon Further Review: Preparing for and Handling an FDA Inspection
World Health Organization
Operationalizing Export Certification and Regionalization Programmes
Understanding the Process of Documenting Informed Consent
Presentation transcript:

Strategies and Concerns in the Sourcing of FDA-Regulated Products, Components & Services Michael A. Swit, Esq. Law Offices of Michael A. Swit 539 Samuel Ct., Suite 229 Encinitas, California ♦ (fax) FDA Counsel.com

BIO 2001 Procurement and Supply Chain Management Seminar Monday, June 25, 2001 San Diego Marriott Hotel and Marina San Diego, California FDA Counsel.com

3 Why Worry About FDA Compliance? FDA Compliance Can Make or Break a Deal Recent Examples: Abbott/Alza Merger Guilford/Gliatech Merger When sourcing you become a “partner” with your vendor -- their problems are yours FDA Counsel.com

4 Why Worry...? FDA mandates you worry about your vendor/partner’s compliance Poor Suppliers May Delay or Void an Approval Active Pharmaceutical Ingredient (“API”) Supplier Sponsor’s application will not be approved if deficiency at API maker FDA Counsel.com

5 Why Worry? Poor Suppliers May Delay or Void an Approval … Active Pharmaceutical Ingredient (“API”) Supplier …. Special tactics/concerns: be extremely careful with first-time suppliers special concern -- if never used before, FDA foreign inspection may delay approval process as well FDA Counsel.com

6 Why Worry…? FDA will make you worry … Poor Suppliers May Delay/Void Approvals... Clinical researchers sponsor’s application may not be approved -- data may be excluded if discovered post-approval, can lead to formal withdrawal of the approval FDA Counsel.com

7 Why Worry? FDA will make you worry … Poor Suppliers May Delay/Void Approvals... Clinical researchers … Special tactics/concerns area of high interest today due to 1999 gene therapy U. of Penn. & problems at other major clinical research centers (e.g., Duke, U. of Colo.) sponsors can not avoid FDA liability via contract -- have to have systems in place to ensure compliance FDA Counsel.com

8 Why Worry…? FDA will make you worry … Poor Suppliers May Delay/Void Approvals … Contract Manufacturers must be GMP compliant or FDA approval can be refused Special tactics/concerns tied directly into your application -- their changes will trigger a regulatory duty that may require an FDA filing/approval may be high volume/low margin producers -- pressure on production may lead to errors FDA Counsel.com

9 Why Worry…? FDA will make you worry … Supplier or component qualification -- Required -- explicitly or implicitly Drugs CFR (a) “…The quality control unit shall be responsible for approving or rejecting drug products manufactured, processed, packed or held under contract by another company.” FDA Counsel.com

10 Why Worry? FDA will make you worry … Supplier or component qualification -- Required -- explicitly or implicitly … Devices CFR “Each manufacturer shall establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements.” FDA Counsel.com

11 Why Worry…? FDA will make you worry … Supplier qualification … Devices CFR (a)(1) -- Evaluation Duty applies to suppliers, contractors and consultants -- evaluated as to abililty to meet specified requirements must define the “type and extent of control” over products, services, suppliers, contractors, and consultants” keep records of acceptable suppliers, contractors & consultants FDA Counsel.com

12 Why Worry…? FDA will make you worry … Supplier qualification … Devices CFR (b) -- Purchasing Data Duty keep data that “clearly describe or reference the specified requirements, including quality requirements, for purchased or otherwise received product and services.” Note: “product” includes components, manufacturing materials, in-process devices, finished devices and returned devices [21 CFR 820.3(r)] FDA Counsel.com

13 Why Worry...? FDA will make you worry … Supplier qualification … Devices CFR (b) -- Purchasing Data Duty Documents “shall include, where possible” an agreement requiring a supplier/contractor/consultant to notify the manufacturer of changes “so that the manufacturer may determine whether the changes may affect the quality of a finished device. FDA Counsel.com

14 Why Worry...? FDA will make you worry … Supplier qualification … Biologics CFR (e) -- Records in “divided” manufacturing each participating manufacturer shall furnish the “last” manufacturer “all records relating to the manufacturing operations performed by such manufacturer insofar as they concern the safety, purity and potency of the lots of the product involved FDA Counsel.com

15 Why Worry? FDA will make you worry … Supplier qualification -- Biologics CFR (e) -- Records in “divided” manufacturing … Tactics/concerns if you’re the “last” mfr. -- defining the records needed re “safety, purity, and potency” -- e.g., does that mean “effectiveness”? be as specific as possible in the supply agreement FDA Counsel.com

16 Why Worry…? FDA will make you worry... Receipt of Components -- Procedures Drugs CFR Testing and Approval or rejection of components, drug product contaniers, and closures number to be tested will depend on … “the past quality history of the supplier” testing can be avoided if: For drug components: ** vendor supplies a Certificate of Analysis showing test results + you do at least one specific identity test ** buyer must establishe reliability of supplier’s analyses via “appropriate validation … at appropriate intervals” FDA Counsel.com

17 Why Worry…? FDA will make you worry... Receipt of Components -- Procedures Drugs -- testing can be avoided if: For container/closure systems -- ** vendor supplies a Certificate of Testing + does visual ID on the container/closure systems ** buyer establishes reliability of supplier’s testing via “appropriate validation of the supplier’s test results at appropriate intervals” FDA Counsel.com

18 Why Worry…? FDA will make you worry... Receipt of Components -- Procedures Devices CFR (b) -- must have procedures for accepting incoming product tested, inspected or otherwise verified to meet specified requirements acceptance or rejection must be documented nonconforming product -- must notify 3rd party manufacturers -- arguably, there must be an investigation Tactics/concerns -- having leverage to make the manufacturer do such an investigation FDA Counsel.com

19 Why Worry…? FDA Problems Can Be Hard to Fix FDA statutory and other powers against violative companies/products may delay or preclude a fix Inspection -- type will determine impact routine vs. directed short vs. lengthy Seizure -- can be least intrusive Injunction consent decrees -- e.g., Abbott litigated orders FDA Counsel.com

20 Why Worry…? FDA Problems Can Be Hard to Fix... Criminal Prosecution -- The sins of your partner may visit upon you -- The E-Ferol Case does not technically preclude supply, but can be so disruptive as to undermine the effectiveness of a vendor Application Integrity Program (AIP) -- [formerly known as the “Alert List” or “Fraud List” if your supplier is on it, can be a lengthy, very subjective process for getting through FDA Counsel.com

21 Why Worry…? FDA Problems Can Be Hard to Fix... Examples Regulatory hurdles -- to cure a problem with an approved product, may require FDA sign- off depending on the nature of the problem. Examples Active pharmaceutical ingredient maker unable to supply: Apparent Solution -- get a new one Problem -- will require prior approval by the agency and additional scientific data to support change Best approach -- have two qualified as early as possible FDA Counsel.com

22 Why Worry…? Products Liability Examples where a supplier caused the problem: Tryptophan -- raw material problem E-Ferol -- poor formulation Carbamazapine -- API process change Securities Liability -- worst case, deal caves; investors (i. e., their lawyers) sue Economic disruption -- you can’t sell if they don’t sell to you FDA Counsel.com

23 Keys to Preventing & Mitigating Problems with FDA-Regulated Suppliers Contract Clauses Audits Surveillance between audits Teamwork at the Buyer FDA Counsel.com

24 Preventing & Mitigating Problems... Contract Clauses Buyer’s right to audit vendor (and vendor’s key suppliers) without notice at any reasonable time during operations vendor to cooperate fully with audit access to records and personnel to be spelled out FDA Counsel.com

25 Preventing & Mitigating Problems … Contract Clauses … advance notice of changes in vendor’s processing -- KEY -- so buyer can assess what regulatory action it must take to keep its approval/submission current

26 Preventing & Mitigating Problems... Contract Clauses... Vendor to cooperate, at no additional expense, with Buyer’s needs to take action to continue to comply with FDA requirements (e.g., vendor to provide data to support filing of supplements to make changes to approved applications) FDA Counsel.com

27 Preventing & Mitigating Problems … Contract Clauses... Vendor’s relations with FDA... Provide copies of 483’s, EIRs prompt notice to buyer of initiation of FDA inspections prompt transmission/notice to buyer of any FDA regulatory correspondence or other regulatory action FDA Counsel.com

28 Preventing & Mitigating Problems... Contract Clauses... Timely notice of other problems encountered by vendor in its manufacturing process timely notice of any adverse reactions or complaints reported to vendor FDA Counsel.com

29 Preventing & Mitigating Problems … Contract Clauses... Contractually articulated duty to comply with FDA laws/regulations general specific -- examples providing certificates of analysis testing to be done FDA Counsel.com

30 Preventing & Mitigating Problems... Contract Clauses... Recalls -- duty to of vendor to cooperate with recalls initiated by buyer (if applicable) representations, warranties, etc. about state of past and present compliance with FDA legal/regulatory reqs. Indemnification duty from vendor to buyer in event of breach of any FDA-related reps or warranties FDA Counsel.com

31 Preventing & Mitigating Problems … Audits -- the key to compliance No notice (ideal world?) Conduct like an FDA inspection Audit team -- should be interdisciplinary in training -- Operations, QA, RA, QC should have an SOP for conducting FDA Counsel.com

32 Preventing & Mitigating Problems... Audits... Written follow-up -- give them a “483” essential get substantive replies from vendor What to stress -- systems specific to your product/service being provided to you by vendor current FDA “hot buttons” FDA Counsel.com

33 Preventing & Mitigating Problems... Audits... Re-audit promptly to confirm corrections General Documents to review chronology of interactions with FDA and other regulatory agencies (e.g., EMEA, HPB, if applicable) all regulatory correspondence/filings between vendor and FDA FDA Counsel.com

34 Preventing & Mitigating Problems … Audits... General Documents to review … minutes of meetings/phone calls with FDA company’s FDA’s (get via FOI if vendor doesn’t have) Tip -- don’t rely just on what the company gives you; seek independent sources of related documents (e.g., under FOI) FDA Counsel.com

35 Preventing & Mitigating Problems... “Surveillance” between audits -- keeping an eye on your vendors Why? “Knowlege is Good” (Faber College motto; Animal House, 1978) -- to be in the best position to anticipate problems To be able to initiate dialogue with vendor as soon as possible after being alerted to a regulatory issue FDA Counsel.com

36 Preventing & Mitigating Problems … “Surveillance” between audits -- keeping an eye on your vendors … How? Read the trade and general press Keep track of FDA warning letters (subscribe to FDA notification services) FOI requests -- direct to FDA or via a third- party service FDA Counsel.com

37 Preventing & Mitigating Problems... Teamwork at the Buyer My old General Counsel’s nightmare -- “here’s the supply contract, we need to sign it today, can you look it over for any legal issues...?” My reply: “Did you run it by RA, QA, QC?” FDA Counsel.com

38 Specific Procurement Problems Imported Components FDA powers to stop questionable imports is much greater than for identical problem presented by a domestic manufacturer Reason -- § 801 of the Federal Food, Drug, and Cosmetic Act gives FDA power to block an import if the product “appears” to be adulterated or misbranded Action can occur without physical examination Example -- bulk APIs going through the New York District Office in past half year have all been detained pending proof they are not counterfeit, adulterated or misbranded -- without physical examination. FDA Counsel.com

39 Specific Problems... Imported Components... Foreign suppliers are harder to sue Tryptophan -- Showa Denko allegedly dodged responsibility for medical syndrome due to being off-shore Sulzer -- foreign parent company allegedly refuses to provide any financial support to its subsidiary (ruptured breast implants) Unusual events impacting supplies -- FDA will try to work with you; examples Phillips Petroleum Plant explosion -- sole source for Marlex -- decreased availability of container/closure systems FDA Counsel.com

40 Specific Problems... Clinical Studies if you’re the sponsor, need deep “down stream” audit systems and contract controls relative to: CRO’s Investigators -- don’t forget to check the FDA list of disqualified investigators IRB’s -- a critical focus today of concerns -- can invalidate data -- PROBLEM -- you may not have a contractual relationship -- insist upon one FDA Counsel.com

41 Specific Problems... API’s (Active Pharmaceutical Ingredients) many are foreign sourced -- thus less frequently inspected by FDA -- puts audit onus on you still subject to all FDA rules -- while API makers technically do not have to meet GMP, there is a fairly stringent ICH guidance make sure contract has API maker notify you of changes to process, etc. that need to be in the DMF and that FDA has been notified FDA Counsel.com

42 Specific Problems... Labels/Labeling label errors are prime cause of recalls your printer must have clear, written procedures on handling of labels, especially if not dedicated to you exclusively intake controls have to be well-documented, trained and validated change control procedures -- even for changes not being submitted for FDA approval -- are essential FDA Counsel.com

43 Questions? Call, , fax or write: Michael A. Swit, Esq. Law Offices of Michael A. Swit 539 Samuel Ct., Suite 229 Encinitas, California ♦ (fax) FDA Counsel.com